DAT-SPECT与MIBG闪烁显像诊断路易体痴呆的诊断准确性:更新系统评价与贝叶斯潜在类别模型荟萃分析
该更新系统评价与贝叶斯潜在类别模型荟萃分析纳入27项研究共2236例患者,评估DAT-SPECT和MIBG心肌闪烁显像诊断路易体痴呆(DLB)的准确性。校正不完美参考标准后,两种影像生物标志物对检测脑内α-突触核蛋白病理及诊断典型临床综合征均具有较高诊断准确性,但校正后特异性普遍低于未校正值。
要点
- 校正不完美参考标准后,DAT-SPECT与MIBG对DLB相关病理和典型临床综合征均显示高敏感性。
- 校正后特异性普遍低于未校正估计,提示未校正准确性可能高估特异性。
- 视觉评估DAT-SPECT诊断典型临床综合征的校正敏感性0.89、特异性0.87。
核心结论
- 校正分析中,DAT-SPECT和MIBG闪烁显像对检测脑内α-突触核蛋白病理及诊断DLB典型临床综合征均具有高诊断准确性。
研究设计与样本
- 更新系统评价与贝叶斯潜在类别模型荟萃分析,文献检索更新至2018年3月18日。
- 共纳入27项研究、2236例患者,两名研究者提取数据并用QUADAS-2工具评价研究有效性。
主要发现
- 除两项涉及死后神经病理验证的DAT-SPECT研究外,研究均易受不完美参考标准偏倚影响。
- 检测脑内α-突触核蛋白病理时,校正后敏感性值与未校正估计相似,而校正后特异性值普遍较低。
- DAT-SPECT视觉评估校正汇总敏感性0.86(95%CrI 0.76-0.95)、特异性0.81(CrI 0.70-0.92);半定量评估分别为0.93(CrI 0.74-1.00)和0.75(CI 0.47-0.94)。
- MIBG延迟相校正汇总敏感性0.92(CrI 0.81-0.99)、特异性0.80(CrI 0.67-0.93);早期相分别为0.87(CrI 0.74-0.98)和0.80(CrI 0.69-0.93)。
- 诊断典型临床综合征时,校正准确性值与未校正估计相似:DAT-SPECT视觉评估敏感性0.89(CrI 0.75-0.98)、特异性0.87(CrI 0.72-0.97);半定量评估分别为0.97(CrI 0.78-1.0)和0.70(CrI 0.43-0.92);MIBG延迟相分别为0.93(CrI 0.81-0.98)和0.90(CrI 0.73-0.97);早期相分别为0.85(CrI 0.66-0.96)和0.96(95%CI 0.83-1.0)。
关键数值与推荐
- DAT-SPECT视觉评估检测α-突触核蛋白病理:校正敏感性0.86(95%CrI 0.76-0.95),特异性0.81(CrI 0.70-0.92)。
- DAT-SPECT半定量评估检测α-突触核蛋白病理:校正敏感性0.93(CrI 0.74-1.00),特异性0.75(CI 0.47-0.94)。
- MIBG延迟相检测α-突触核蛋白病理:校正敏感性0.92(CrI 0.81-0.99),特异性0.80(CrI 0.67-0.93)。
- MIBG早期相检测α-突触核蛋白病理:校正敏感性0.87(CrI 0.74-0.98),特异性0.80(CrI 0.69-0.93)。
- 诊断典型临床综合征:DAT-SPECT视觉评估敏感性0.89(CrI 0.75-0.98)、特异性0.87(CrI 0.72-0.97);MIBG延迟相敏感性0.93(CrI 0.81-0.98)、特异性0.90(CrI 0.73-0.97)。
临床怎么用
- 对于疑诊DLB患者,DAT-SPECT和MIBG闪烁显像均可作为支持诊断的影像生物标志物。
- 解读结果时应考虑不完美参考标准可能高估特异性,校正后的特异性估计更保守。
- 视觉评估与半定量评估、MIBG延迟相与早期相各有不同的敏感性与特异性表现,可结合临床场景选择。
局限性
- 除两项DAT-SPECT研究有死后神经病理验证外,多数研究易受不完美参考标准偏倚影响。
- 文献检索截至2018年3月18日,未纳入此后发表的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Imperfect clinical reference standards can preclude accurately estimating the diagnostic accuracy of DAT-SPECT and MIBG myocardial scintigraphy for diagnosing DLB. To investigate the validity of unadjusted accuracy, we updated our previous meta-analysis. METHODS: Literature search was updated to March 18, 2018. We also examined published systematic review reports. Two investigators extracted data and rated study validity using the QUADAS-2 tool. We performed a Bayesian latent class model meta-analysis accounting for imperfect reference standards. RESULTS: We evaluated 27 studies including 2236 patients. With the exception of two DAT-SPECT studies that involved postmortem neuropathological verification, studies were susceptible to bias from imperfect reference standards. Compared with the unadjusted accuracy estimates, the adjusted sensitivity values were similar, whereas the adjusted specificity values were generally lower for detecting α-synuclein pathology in the brain. The adjusted summary sensitivity and specificity were 0.86 (95% credible interval [CrI], 0.76-0.95) and 0.81 (CrI, 0.70-0.92), and 0.93 (CrI, 0.74-1.00) and 0.75 (CI, 0.47-0.94) for visual and semi-quantitative assessments of DAT-SPECT, respectively; 0.92 (CrI, 0.81-0.99) and 0.80 (CrI, 0.67-0.93), and 0.87 (CrI, 0.74-0.98) and 0.80 (CrI, 0.69-0.93), for delayed- and early-phase scans of MIBG scintigraphy, respectively. When diagnosing the typical clinical syndrome, the adjusted accuracy values were similar to the unadjusted estimates. The adjusted sensitivity and specificity were 0.89 (CrI, 0.75-0.98) and 0.87 (CrI, 0.72-0.97), and 0.97 (CrI, 0.78-1.0) and 0.70 (CrI, 0.43-0.92) for visual and semi-quantitative assessments of DAT-SPECT, respectively; and 0.93 (CrI, 0.81-0.98) and 0.90 (CrI, 0.73-0.97), and 0.85 (CrI, 0.66-0.96) and 0.96 (95% CI, 0.83-1.0) for delayed- and early-phase scans of MIBG scintigraphy, respectively. CONCLUSIONS: In our adjusted analyses, both imaging biomarkers had high diagnostic accuracy for detecting the hallmark pathology in the brain and for diagnosing the typical clinical syndrome.
引用
- Nihashi T, Ito K, Terasawa T, et al. Diagnostic accuracy of DAT-SPECT and MIBG scintigraphy for dementia with Lewy bodies: an updated systematic review and Bayesian latent class model meta-analysis. Eur J Nucl Med Mol Imaging. 2019. PMID: 31423561. doi:10.1007/s00259-019-04480-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。